Investors

Experience the forefront of technological innovation through our startup. Partner with us to shape the future of neurodegenerative disease diagnostics with a promising and strategic investment in our growth.

The Challenge

Neurodegenerative diseases (NDs) in humans and animals are increasing. Beyond devastating health impacts, NDs are forecasted to cost the global economy over $9 trillion by 2050. Pre-symptomatic diagnostics are scarce, preventing new therapeutic and control strategies. 

The Solution

Priogen is revolutionizing ND protein biomarker detection through innovative technologies and services that enable advancements in pre-symptomatic detection and treatment. With proprietary hardware, software, and molecular reagents, Priogen excels in detecting multiple ND protein biomarkers. Applications span ante-mortem liquid and tissue biopsies, post-mortem tissues, and environmental detection. Priogen is at the forefront of biomarker detection technology.


The Team

We have an innovative, diverse, and highly productive team that has worked together for 6 years. Our core values are: 1) Function as a team, 2) Communicate openly and honestly, 3) Work with dedication, 4) Innovate with purpose, 5) Swift execution yields results.

The Foundation

We have established the foundation for a formidable corporation poised to lead the industry in protein diagnostics. Our achievements include a solid revenue stream, an expanding customer base, numerous technological breakthroughs, functional prototypes, diverse product offerings, secured funding from venture capitalists and private investors, and a strategic, methodical rollout of services and technologies.


TAM: $72.5B USD 

 Current Status

Competitive Advantage

Keep up with our socials

TwitterLinkedInFacebook